T o screen or not to screen? For prostate cancer, that is still the question, despite the release this spring of mortality data from two large trials that asked whether prostate-specifi c antigen (PSA) testing reduces the risk of dying from prostate cancer. In the United States, the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial found no mortality benefi t for PSA screening after 7 -10 years. Across the Atlantic, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 20% mortality benefi t after 10 years of PSA screening. Both studies were published in the March 26, 2009, New England Journal of Medicine .
The data generated conflicting responses. The American Cancer Society (ACS) continued to not recommend routine screening. Instead, the ACS endorses shared decision making, with men and their physicians discussing the pros and cons of PSA screening before deciding on the blood test. The American Urological Association, by contrast, lowered to 40 years the age that "relatively healthy, wellinformed" men should begin PSA testing. And a coalition of 13 advocacy groups focused on prostate cancer released a joint statement encouraging men to discuss the risk for prostate cancer with their physicians "and to request the appropriate use of PSA and DRE [digital rectal examination] tests until better options are available."
Ruth Etzioni, Ph.D., a biostatistician at Fred Hutchinson Cancer Research Center in Seattle, said that interpretation of the two trials amounts to an oncologic Rorschach test: "The evidence is such that those people who are skeptical will still be skeptical, and those people who are enthusiastic will find something to be enthusiastic about." Whether either fi nding will affect actual practice is unknown. For men older than 50 years, PSA testing "is very common and I don't think it's going to change very much. It's been very deeply ingrained in our practices for the last 10 -15 years," said Gerald Andriole, M.D., fi rst author of the PLCO report and chief of the division of urologic surgery at the Washington University School of Medicine in St. Louis. Other PLCO authors include JNCI editor-inchief Barnett Kramer, M.D., associate director for disease prevention at the National Institutes of Health in Bethesda, Md.
First Draft
Investigators for the PLCO trial, which begin in 1992 and enrolled nearly 77,000 men, caution that the published results are an initial report, with more data to come. Ideally, overall follow-up would stretch to 13 -15 years, said Andriole. "These are initial results," he said, published after the trial's data safety monitoring board determined no mortality benefi t existed for men receiving PSA tests annually for six years. "There's still a possibility for the group as a whole that screening will be benefi cial." Chris Berg, M.D. , from the Division of Cancer Prevention at the National Cancer Institute, said that NCI will continue to fund the trial until all men have been monitored for at least 13 years. Berg, one of the study authors, helps run the PLCO. Prostate cancer often takes a long time to develop and progress, Berg said, so the current 7 -10 years of follow-up is too short to know exactly what effect screening may ultimately have.
Four researchers interviewed for this article said they think that PSA testing does offer a mortality benefi t for certain menbut that, for now, there's no way to know "Somewhere in the PLCO repository is the answer to this dilemma."
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"There are a lot of men who have 'toothless lions, ' meaning slow-growing, indolent tumors," Berg said. "They aren't the kind that metastasize. We've known that those exist." And those men have the most to lose with screening: Surgery and antiandrogen drugs can leave them impotent and incontinent even though their cancer wouldn't have killed them.
For this reason, Andriole recommends that men with a short life expectancy not be screened. "For elderly or sick men, we should really stop screening," he said. "If they don't have a great chance of surviving 10 years or so, we may be doing more harm than good." The United States Preventive Services Task Force (USPSTF), which authors evidencebased screening guidelines, agrees in principle. Last August, the group updated its prostate cancer screening prevention guidelines to recommend, for the fi rst time, against PSA testing for men aged 75 years and older. The task force continues to state that the evidence is insuffi cient to recommend for or against screening in younger men. Andriole thinks that recommendation should be extended to younger men who smoke or have diabetes or other health conditions that shorten life expectancy. The USPSTF group's next update isn't scheduled until 2013, but it's possible that they could convene a special panel to consider the new data, said Etzioni.
One reason that the data from PLCO proved less conclusive than many had hoped rests with the popularity of PSA testing. Even though a prostate cancer mortality benefi t has always been in doubt, the numbers of men getting the test skyrocketed in the early 1990s, said Etzioni, referring to Medicare data. "It went from practically zero to 30% in 2 years for men over 65," she said.
Such enthusiasm meant that many men in the control, or "community care," arm of the PLCO trial received PSA testing anyway. The trial was designed to provide annual screening for men in the screening arm, and about 85% of those men received PSA tests. But in the community care arm, about 50% of men also received PSA tests, so the trial lost its original power to detect whether annual screening saves lives in comparison with no screening. "Some say this is a test of aggressive screening -every year for 6 years -versus not-so-aggressive screening," said Andriole.
Added Berg, "Ideally, you want no screening versus 100% screening." Achieving this goal is diffi cult in a country in which prostate cancer screening has been heavily promoted.
European Trial
By contrast, in the European study, many fewer men in the control arm appear to have received PSA testing (although this "contamination rate" is not reported). This fi nding led to a larger gap in the number of prostate cancers diagnosed between the two arms in the European study than in the PLCO trial. In turn, that gap may have led to the mortality benefi t. "If you start screening in a population that hasn't been screened, you have more to gain," said Etzioni.
Also, the European trial used a lower cutoff for a positive PSA test, sending men for biopsies when their PSA levels hit 3 ng/ mL, albeit at less frequent intervals. In the PLCO, the cutoff was 4 ng/mL. This difference also helps account for the discrepancy between the trials, said Etzioni. However, the lower cutoff value also probably led to "more costs," meaning more unnecessary treatment in men who didn't need it.
For these reasons, Otis Brawley, M.D., chief medical offi cer at ACS, doesn't "see the two studies being at odds with each other." Brawley said that he's been disappointed by the reaction of urologists, in particular, to the new data.
"I think there is too much prostate cancer screening going on. As the medical community absorbs this information, I hope there will be more shared decision making," meaning that physicians will "try to understand the patient's desires and concerns, try to explain the state of the science, and then try to come to a mutual understanding of what should be done."
However, Brawley is pessimistic that this will happen frequently because, he said, physicians generally don't have enough time or enough knowledge regarding the pros and cons of screening. "We've got to have a wholesale education of physicians, objective education of physicians about the potential risk and the potential benefi ts of screening," he said.
Moving Ahead
Despite the continuing controversy -the debate over PSA testing has raged for 20 years -researchers in the fi eld see hope for untangling the issues. They point to mathematical modeling and the huge repository of biological samples from the PLCO as two resources ripe for tapping.
Mathematical modeling takes trial data and then builds an ideal scenario, said Berg. For instance, modelers can input data from PLCO and construct a virtual trial that compares hypothetical men who receive no screening to men who get screened annually. Etzioni, who develops such models, is building one that will "quantify the expected savings [of life] of a 50-year-old man if he does get screened versus the expected likelihood of an unnecessary diagnosis." Etzioni's models may answer other questions, such as whether a 3-ng/mL cutoff or a 4-ng/mL cutoff offers more benefi t, and whether annual PSA testing is necessary or if less frequent testing would suffi ce. Her work is supported by NCI's Cancer Intervention and Surveillance Modeling Network (CISNET), which funds other researchers ' building similar models.
Modeling is becoming more accepted as a tool to extend clinical trial results, according to Berg. For instance, the USPSTF used models when building their colorectal and breast cancer screening guidelines. Models are "not as good as clinical trials," said Berg. "But we cannot do a trial of the size and scope of PLCO to answer every question."
Berg also pointed to the PLCO's vast repository of blood, DNA, and prostate biopsy and tumor samples. She encourages researchers to mine these resources for clues as to which tumors are toothless lions and which need swift treatment. Finding biomarkers to tell which tumors belong in which categories is key to improving the value of PSA screening, she said. Although several such markers are under investigation, none has yet proven its worth in the clinic. "Somewhere in the PLCO biorepository is the answer to this dilemma," she said, "if only we were smart enough to fi gure it out."
